


## Curriculum Vitae

<b>Name</b>	<b>Jean-Charles SORIA</b>	
<b>Current Position &amp; Affiliation</b>	<b>Amgen Headquarter</b>	
<b>Country</b>	<b>USA</b>	

### Educational Background

2017-2018 **Managing Health Care Delivery**. Harvard Business School diploma  
 Nov 2001 **Ph .D. Degree** in the Fundamental Basis of Oncogenesis, South Paris Univeristy XI  
 Oct. 2001 **ESMO Board Certification** in Medical Oncology  
 1999-2001 **Postdoctoral Fellowship**, University of Texas M.D. Anderson Cancer Center, Houston, Texas. Thoracic Head and Neck Medical Oncology Department. Laboratory of Molecular Biology  
 Sept. 1999 **French Board Certificate** in Medical Oncology  
 June 1999 **FECS, ASCO and AACR certification** for the Workshop “Methods in Clinical Cancer Research”, Flims, Switzerland  
 1998 **Master’s of Science** in the Fundamental Basis of Oncogenesis, South Paris Univeristy XI  
 1997 **M.D. Degree**. Thesis: “Squamous cell carcinoma of the penis: natural history, prognostic factors and results. About a 102 patients treated at the Gustave-Roussy Institute with a conservative approach.” René-Descartes University, Paris V  
 1994-1999 **Medical Oncology Residency and Fellowship**, Ambroise Paré Hospital, Boulogne ; Henri Mondor Hospital, Creteil ; Hôtel-Dieu Hospital, Paris ; Institut Gustave-Roussy, Villejuif ; Institut Curie, Paris ; Tenon Hospital, Paris ; Hopital Saint Louis, Paris.  
 1994 **Bachelor’s of Science** in Molecular Biology and Biochemistry, René-Descartes University, Paris V  
 1988-1994 **School of Medecine**, Best student at the admission competitive examination, René-Descartes University, Paris V, France  
 1988 **Baccalaureat in Sciences**, Victor Duruy, High School, Paris, France

## Professional Experience

Since 2020 **General Director**, Gustave Roussy, Villejuif - FRANCE  
2017-2019 **Senior Vice President, Oncology Research & Development, AstraZenca**, Gaithersburg, Maryland, USA  
2015 -2017 **Elected member of the French National Council of Universities (CNU section 47-02)**  
2015-today **Member of the International Medical Council of Lourdes**  
2013 -2017 **Chairman Drug Development Department (DITEP)**, Gustave Roussy, Villejuif, France  
Since 2013 **Adjunct Professor**, University of Texas MDACC - Houston, USA  
2012 -2017 **Director of SIRIC** - Sites Dedicated to Integrated Research in Cancer  
2008-2013 **Chief of SITEP (Drug Development Unit)**, Gustave Roussy, Villejuif 2 |  
Since 2006 **Full Professor of Medicine and Medical Oncology**, South Paris Univeristy XI, Gustave Roussy  
2001 - 2006 **Assistant and Associate Professor of Medicine and Medical Oncology**, South Paris Univeristy XI, Gustave Roussy

## Professional Organizations

Since 2017 **Elected member** of the Academy of Europe  
Since 2013 **Elected member** of the Academy of Cancer Sciences  
2008-2009 **Member of the executive committee** of ESMO  
2008-2009 **Chairman** of the National Representatives Committee of ESMO  
2008-2009 **National representative** for France within ESMO  
2002-2004 **Member of the Scientific Council** of the Charity Association “Ligue Contre le Cancer, Comité de l’Essonne”  
2001-2003 **President** of the Flims Alumni Club October  
1999-2001 **Member of the steering committee** of the Postdoctoral Association at M.D. Anderson Cancer Center  
Sept. 1999 **Member** of the American Society of Clinical Oncology  
June 1998 **Member** of the American Association for Cancer Research  
1998 **President** of the Medical Resident’s and Fellow’s Association of Paris  
1995-1998 **Founding member and Secretary** of the French Resident’s and Fellow’s Association for Teaching and Research in Oncology (AERIO)  
Sept. 1997 **Member** of the European Society for Medical Oncology

## Main Scientific Publications

1. Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Lorient Y, Tselikas L, Gazzah A, Rouleau E, Adam J, Michiels S, Massard C, André F, Olaussen KA, Vassal G, Howarth K, Besse B, **Soria JC**, Friboulet L, Planchard D. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. *Eur J Cancer*. 2020 Jun;132 : 211-223.
2. Ramalingam SS, **Soria JC**. Osimertinib in EGFR-Mutated Advanced NSCLC. Reply. *N Engl J Med*. 2020 May;382(19) : 1864-1865.
3. Scotté F, Minvielle E, Mir O, André F, Barlesi F, **Soria JC**. A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19-positive patients with cancer. *Eur J Cancer*. 2020 Jun;132 : 1-4.
4. Calabrò L, Peters S, **Soria JC**, Di Giacomo AM, Barlesi F, Covre A, Altomonte M, Vegni V, Gridelli C, Reck M, Rizvi N, Maio M. Challenges in lung cancer therapy during the COVID-19 pandemic. *Lancet Respir Med*. 2020 Jun;8(6) : 542-544.
5. Isakoff SJ, Tabernero J, Molife LR, **Soria JC**, Cervantes A, Vogelzang NJ, Patel MR, Hussain M, Baron A, Argilés G, Conkling PR, Sampath D, Maslyar D, Patel P, Chan W, Gendreau S, Musib L, Xu N, Ma H, Lin K, Bendell J. Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. *Ann Oncol*. 2020 May;31(5) : 626-633.
6. Michot JM, Lappara A, Le Pavec J, Simonaggio A, Collins M, De Martin E, Danlos FX, Ammari S, Cauquil C, Ederhy S, Barreau E, Belkhir R, Berdelou A, Lazarovici J, Chanson P, Izzedine H, Seferian A, Le Pajolec C, Baldini C, Martin-Romano P, Mariette X, Robert C, Besse B, Hollebecque A, Varga A, Laghouati S, Mateus C, Voisin AL, **Soria JC**, Massard C, Marabelle A, Champiat S, Lambotte O. The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. *Eur J Cancer*. 2020 May;130 : 39-50.
7. Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, **Soria JC**, Massard C, Marabelle A. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. *Eur J Cancer*. 2020 Apr;129 : 71-79.

8. Martin-Romano P, Castanon E, Ammari S, Champiat S, Hollebecque A, Postel-Vinay S, Baldini C, Varga A, Michot JM, Vuagnat P, Marabelle A, **Soria JC**, Ferté C, Massard C. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. *Cancer Med.* 2020 Apr;9(8) : 2643-2652.
9. Yver A, Agatsuma T, **Soria JC**. The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers. *Ann Oncol.* 2020 Mar;31(3) : 430-434.
10. Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, Le Tourneau C, Sablin MP, Lacroix L, Enrico D, Miran I, Jovelet C, Bièche I, **Soria JC**, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. *Ann Oncol.* 2020 Mar;31(3) : 377-386.
11. Varga A, **Soria JC**, Hollebecque A, LoRusso P, Bendell J, Huang SA, Wagle MC, Okrah K, Liu L, Murray E, Sanabria-Bohorquez SM, Tagen M, Dokainish H, Mueller L, Burris H. A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. *Clin Cancer Res.* 2020 Mar;26(6) : 1229-1236.
12. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, **Soria JC**; FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *N Engl J Med.* 2020 Jan; 382(1) : 41-50.
13. Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong KK, Yarden Y, Casanova E, **Soria JC**, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. *J Clin Invest.* 2020 Feb;130(2) : 612-624.
14. Chargari C, Levy A, Paoletti X, **Soria JC**, Massard C, Weichselbaum RR, Deutsch E. Methodological Development of Combination Drug and Radiation Therapy in Basic and Clinical Research. *Clin Cancer Res.* 2020 Sep 15; 26(18):4723-4736.

15. van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, **Soria JC**, Tabernero J, Caldas C, Voest EE. Caring for patients with cancer in the COVID-19 era. *Nat Med.* 2020 May; 26(5) : 665-671.
16. Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, **Soria JC**, Massard C, Ammari S. Patterns of progression in patients treated for immuno-oncology antibodies combination. *Cancer Immunol Immunother.* 2020 Jul 22. doi: 10.1007/s00262-020-02647-z.
17. Martin-Romano P, Ammari S, El-Dakdoukti Y, Baldini C, Varga A, Vuagnat P, Angevin E, Bahleda R, Gazzah A, Champiat S, Michot JM, Postel-Vinay S, Marabelle A, **Soria JC**, Boige V, Malka D, Ducreux M, Massard C, Hollebecque A. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. *Eur J Cancer.* 2020 Sep;137:117-126. doi: 10.1016/j.ejca.2020.06.030.
18. Postel-Vinay S, Massard C, **Soria JC**. Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management? *Eur J Cancer.* 2020 Sep;137:235-239. doi: 10.1016/j.ejca.2020.07.009.
19. Boutros C, Chaput-Gras N, Lanoy E, Larive A, Mateus C, Routier E, Sun R, Tao YG, Massard C, Bahleda R, Schwob D, Ibrahim N, Khoury Abboud RM, Caramella C, Lancia A, Cassard L, Roy S, **Soria JC**, Robert C, Deutsch E. Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma. *J Immunother Cancer.* 2020 Aug;8(2):e000627. doi: 10.1136/jitc-2020-000627.
20. Sheth S, Gao C, Mueller N, Angra N, Gupta A, Germa C, Martinez P, **Soria JC**. Durvalumab activity in previously treated patients who stopped durvalumab without disease progression. *J Immunother Cancer.* 2020 Aug;8(2):e000650. doi: 10.1136/jitc-2020-000650.
21. Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, **Soria JC**, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, Niederfellner G, Méresse Naegelen V, Pastan I. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. *Cancer.* 2020 Nov 15;126(22):4936-4947. doi: 10.1002/cncr.33145

22. Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D, Remon J, Sangaletti S, Proto C, Garassino MC, **Soria JC**, Marabelle A, Voisin AL, Farhane S, Besse B, Chaput N. Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. *Clin Cancer Res.* 2020 Sep 4. doi: 10.1158/1078-0432.CCR-20-142.
23. Azaro A, Baldini C, Rodon J, **Soria JC**, Yuen E, Lithio A, Oakley G, Benhadji KA, Massard C. Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. *Invest New Drugs.* 2020 Sep 11. doi: 10.1007/s10637-020-00944-z.
24. Mir O, Watson S, Massard C, Le Cesne A, Benhadji KA, **Soria JC**. Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients. *Ann Oncol.* 2020 Dec;31(12):1782-1784. doi: 10.1016/j.annonc.2020.09.003.
25. Recondo G, Mahjoubi L, Maillard A, Loriot Y, Bigot L, Facchinetti F, Bahleda R, Gazzah A, Hollebecque A, Mezquita L, Planchard D, Naltet C, Lavaud P, Lacroix L, Richon C, Lovergne AA, De Baere T, Tselikas L, Deas O, Nicotra C, Ngo-Camus M, Frias RL, Solary E, Angevin E, Eggermont A, Olaussen KA, Vassal G, Michiels S, Andre F, Scoazec JY, Massard C, **Soria JC**, Besse B, Friboulet L. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. *NPJ Precis Oncol.* 2020 Sep 8;4:27. doi: 10.1038/s41698-020-00130-7.
26. Jazieh AR, Chan SL, Curigliano G, Dickson N, Eaton V, Garcia-Foncillas J, Gilmore T, Horn L, Kerr DJ, Lee J, Mathias C, Nogueira-Rodrigues A, Pierce L, Rogado A, Schilsky RL, **Soria JC**, Warner JL, Yoshida K. Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. *JCO Glob Oncol.* 2020 Sep;6:1461-1471.
27. Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Rouyar A, Milic M, Carré A, Battistella E, Alvarez Andres E, Niyoteka S, Romano E, Louvel G, Durand-Labrunie J, Bockel S, Bahleda R, Robert C, Boutros C, Vakalopoulou M, Paragios N, Frey B, **Soria JC**, Massard C, Fertet C, Fietkau R, Ost P, Gaipl U, Deutsch E. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. *J Immunother Cancer.* 2020 Nov;8(2):e001429.